### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type R	Responses	s)													
1. Name and Address of Reporting Person * THALENFELD BARBARA E				F	2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) C/O ENZO BIOCHEM INC, 527 MADISON AVE				~ ~ ~ .	3. Date of Earliest Transaction (Month/Day/Year) 04/19/2004						X Officer (give title below) Other (specify below)  VP, Corporate Development				
(Street)				4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
NEW YORK	K, NY 1		(7: \												
(City)		(State)	(Zip)		T	able I - No	n-Dei	rivative S	Securities	s Acqui	ired, Disp	osed of, or I	Beneficially (	Owned	
1.Title of Security (Instr. 3)		2. Transacti Date (Month/Day	//Year) E	•	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)			D) Beneficially Owned Following Reported Transaction(s)			6. Ownership Form:	7. Nature of Indirect Beneficial	
				Month/Day/Year	Code	V	Amoun	(A) or t (D)	Price	(Instr. 3 a	ind 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common Stock, par value \$.01 per share		04/19/200	)4		P	·	3,350 (1)	· /		(2)	D				
			Tal		erivative Securit		ed, D	isposed (	of, or Ber	neficial	·		trol number		
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		3. Transact Date (Month/Da	Execu y/Year) any	eemed	4. Transaction Code	5.	6. D and (Mc	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownersh Form of Derivativ Security Direct (I or Indire	Beneficia Ownershi (Instr. 4)
					Code V	(A) (D)	Date Exe	_	Expiratio Date	Title	Amount or Number of Shares				
Reportii	ng O	wners			Relations	hins									

Other

## Signatures

527 MADISON AVE NEW YORK, NY 10022

Reporting Owner Name / Address

THALENFELD BARBARA E C/O ENZO BIOCHEM INC

Dr. Barbara E. Thalenfeld	04/19/2004
**Signature of Reporting Person	Date

10%

Owner

Officer

VP, Corporate Development

Director

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person exercised these stock options which were granted pursuant to Enzo Biochem's Stock Option Plan.
- (2) As of the date hereof, the Reporting Person directly beneficially owns 1,710 shares of Common Stock, 2,552 shares of Common Stock in Enzo Biochem's 401K plan and 48,855 options to purchase Common Stock, par value \$.01 per share which are currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.